Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity treatments improve.

Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity treatments because a wide swath of the population could be eligible to take them, and patients have to stay on the drugs to keep the weight off.

Ozempic, Mounjaro and Wegovy may not be the lightbulb, jet airplane or internet, but their impact is expected to be so significant it could shift GDP.

Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.

Consumer Reports looked at how weight loss drugs and possible side effects in older adults. The Lavi: A jet built to dominate the skies but grounded by politics. Designed to ensure air supremacy, Israel’s cutting-edge fighter combined incredible agility,